Journal of Antimicrobial Chemotherapy · 2014 · 56 citations · 12 references
PharmacyPharmacotherapyToxicologyBone MetabolismRenal PharmacokineticsRenal PharmacotherapyAntiviral TherapyInterferon-based TherapyRenal DiseaseRenal ToxicityViral HepatitisViral Hepatitis TreatmentAntiviral Drug NephrotoxicityBone Mineral Density DeclineChronic Viral HepatitisGlomerular Filtration Rate MeasurementHepatitis B TherapyKidney DiseasesProteinuria ReductionTenofovir Therapy
OBJECTIVES: Nucleotide analogues may promote renal and bone toxicity. The aim of the present study was to evaluate markers of osteorenal toxicity in patients affected by hepatitis B virus-related chronic hepatitis treated with lamivudine plus adefovir who were switched to tenofovir. PATIENTS AND METHODS: We evaluated 60 consecutive patients at the time of the switch of treatment and after 1, 3, 6, 9 and 12 months. The mean baseline estimated glomerular filtration rate (eGFR) was 89.3 ± 19.0 mL/min/1.73 m(2). RESULTS: During the study period we observed a reduction in mean eGFR up to 6 months after switching to tenofovir, and this remained stable for the last two timepoints. At the end of study, the mean eGFR was 82.6 ± 21.5 mL/min/1.73 m(2), a reduction of 7.5%. The mean baseline proteinuria was 202.6 ± 237.6 mg/24 h. Microhaematuria was observed in 22.6% of patients and hypophosphataemia in 18.6%. After 1 month of tenofovir, we observed a worsening of serum phosphate and parathyroid hormone levels, haemoglobinuria and 24 h proteinuria. After 3 and 12 months of tenofovir, these data tended to recover to baseline levels. A total of 92.6% of patients at baseline had hypovitaminosis D. After supplementation with cholecalciferol, this percentage decreased significantly. We observed a reduced bone mineral density (BMD) in 52.7% of patients at baseline; this increased to 77.8% after 6 months of tenofovir, but at the last timepoint the percentage of patients with a reduced BMD had fallen to a level above the baseline. CONCLUSIONS: In conclusion, patients exposed to lamivudine plus adefovir showed relevant osteorenal damage. The switch to tenofovir provoked a slight reduction in eGFR that stabilized after 6 months. The reduced BMD at baseline did not worsen under tenofovir treatment.
12
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid et al. · Annals of Internal Medicine · 2009 · 25.7K citations
Pharmacy, Nephrology, Physiology +12
Mechanism of Active Renal Tubular Efflux of Tenofovir
Adrian S. Ray, Tomáš Cihlář, Kelly L. Robinson et al. · Antimicrobial Agents and Chemotherapy · 2006 · 325 citations · Full text